Acad Radiol. 2025 Oct 27:S1076-6332(25)00962-6. doi: 10.1016/j.acra.2025.10.006. Online ahead of print.
ABSTRACT
RATIONALE AND OBJECTIVES: To develop and validate an interpretable radiomics model based on pituitary MRI to predict growth hormone deficiency (GHD) in children with short stature.
METHODS: This retrospective multicenter study enrolled 202 children (105 GHD, 97 idiopathic short stature [ISS]) as an internal cohort (7:3 ratio for training/testing cohorts) from institution I, and 138 children (61 GHD, 77 ISS) from institution II and institution III as an external validation cohort. Radiomics features were selected by SelectKBest and least absolute shrinkage and selection operator (LASSO), subsequently used to construct six machine learning models. Diagnostic performance of model was evaluated by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and calibration curves. The interpretability of the model was assessed using Shapley additive explanations (SHAP).
RESULTS: A total of 17 radiomics features were selected. Among all classifiers, support vector machine (SVM)-based radiomics model exhibited the highest diagnostic performance, with AUCs of 0.877 (95% CI: 0.813, 0.928), 0.878 (95% CI: 0.786, 0.951), and 0.885 (95% CI: 0.833, 0.937) in training, testing, and external validation cohorts, respectively. The SVM-integrated clinical-radiomics model yielded comparable efficacy, with AUCs of 0.874 (95% CI: 0.812, 0.928), 0.878 (95% CI: 0.786, 0.952), and 0.889 (95% CI: 0.830, 0.939) across the same cohorts. Both radiomics-based models significantly outperformed the clinical model (all p<0.001), while no statistically significant difference was observed between the radiomics and clinical-radiomics models (all p>0.05). The SHAP analysis identified three key radiomics features with significant differences between GHD and ISS groups (all p<0.001).
CONCLUSIONS: The interpretable radiomics-driven SVM model effectively predicts GH levels, providing a clinically viable, non-invasive alternative to GH stimulation test in children with short stature.
PMID:41152101 | DOI:10.1016/j.acra.2025.10.006
